OncoMatch/Clinical Trials/NCT03731442
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Is NCT03731442 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Paclitaxel and Platinum for esophageal cancer.
Treatment: Paclitaxel · Platinum · PEG-rhG-CSF — Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery. However, the recurrence rate is as high as 23.8%-58%, and the median time-to-recurrence is about 10.5 months. In patients who had residual tumor after surgery, evidence lacks for chemoradiation. The aim of the study is to evaluate the efficacy and safety of chemoradiation therapy in patients with recurrences after radical surgery or palliative surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Prior therapy
Must have received: surgery — radical or palliative
Locoregional recurrence after radical surgery; Positive resection margin (R1/R2) after surgery
Cannot have received: any therapy after recurrence
No prior therapy after recurrence
Lab requirements
Blood counts
White blood cell count > 4.0*10^9/L; abnormal CBC test [excluded]
Kidney function
Sufficient kidney function
Liver function
Sufficient liver function
Sufficient liver and kidney functions; White blood cell count > 4.0*10^9/L; Insufficient liver or kidney functions, or abnormal CBC test [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify